Literature DB >> 1341993

The postantibiotic effect.

J M Spivey1.   

Abstract

The factors that affect the presence and duration of the post-antibiotic effect (PAE) for different antimicrobial agents are described, and the clinical importance of the PAE is discussed. Proposed mechanisms by which the PAE occurs include both nonlethal damage induced by the antimicrobial agent and a limited persistence of the antimicrobial agent at the bacterial binding site. The specific microorganism-antimicrobial combination is the most important factor to influence the presence and duration of the PAE. Additional factors are antimicrobial combinations and experimental conditions, including the antimicrobial concentration and the length of the antimicrobial exposure. Most antimicrobial agents produce a PAE when tested against gram-positive cocci. However, against gram-negative bacilli, beta-lactam antibiotics (except for imipenem) have a minimal, or even a negative, PAE. Aminoglycosides, inhibitors of protein and nucleic acid synthesis, and fluoroquinolones have PAEs against gram-negative bacteria that range from one to four hours. In vivo PAEs are generally longer than in vitro PAEs for the same microorganism-antimicrobial combination. In human studies, aminoglycosides, which have an extended PAE against gram-negative bacilli, have been effective when given in once-daily dosing regimens that allow serum drug concentrations to fall below the minimum inhibitory concentration. Extending the dosing interval of an antimicrobial agent that has a PAE has several potential advantages, among them reduced cost, less toxicity, and better compliance among outpatients receiving antimicrobial therapy. Although data are limited, animal and human studies provide support for the clinical importance of the PAE. Further research into the impact of the PAE on antimicrobial dosing, efficacy, toxicity, and costs is warranted.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1341993

Source DB:  PubMed          Journal:  Clin Pharm        ISSN: 0278-2677


  25 in total

Review 1.  Methods of minimising the cost of aminoglycoside therapy to hospitals.

Authors:  C A Gentry; K A Rodvold; J S Bertino
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

2.  Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture.

Authors:  M Nascimbeni; C Lamotte; G Peytavin; R Farinotti; F Clavel
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

3.  Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.

Authors:  Jayesh Bhatt; Nikki Jahnke; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2019-09-04

Review 4.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 5.  Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation.

Authors:  A Sánchez-Navarro; M M Sánchez Recio
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

Review 6.  Destination of aminoglycoside antibiotics in the 'post-antibiotic era'.

Authors:  Yoshiaki Takahashi; Masayuki Igarashi
Journal:  J Antibiot (Tokyo)       Date:  2017-10-25       Impact factor: 2.649

Review 7.  Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.

Authors:  Richard S Slavik; Peter J Jewesson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Antimicrobial pharmacokinetics in endophthalmitis treatment: studies of ceftazidime.

Authors:  T A Meredith
Journal:  Trans Am Ophthalmol Soc       Date:  1993

9.  In vitro activity and in vivo efficacy of clavulanic acid against Acinetobacter baumannii.

Authors:  Alejandro Beceiro; Rafael López-Rojas; Juan Domínguez-Herrera; Fernando Docobo-Pérez; Germán Bou; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

10.  Antimicrobial Peptide Novicidin Synergizes with Rifampin, Ceftriaxone, and Ceftazidime against Antibiotic-Resistant Enterobacteriaceae In Vitro.

Authors:  Odel Soren; Karoline Sidelmann Brinch; Dipesh Patel; Yingjun Liu; Alexander Liu; Anthony Coates; Yanmin Hu
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.